{"id":"W2998319702","doi":"10.1016/j.jaad.2019.12.038","title":"Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis","year":2019,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":61,"is_retracted":false,"has_abstract":false,"ca_institutions":"SKiN Health","funders":"Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Psoriasis Area and Severity Index; Ustekinumab; Secukinumab; Etanercept; Psoriasis; Adalimumab; Infliximab; Cumulative dose; Anakinra; Internal medicine; Dermatology; Psoriatic arthritis; Tumor necrosis factor alpha; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005809945,0.002123242,0.01125466,0.001430061,0.0002456169,0.001716414,0.001462543,0.001390351,0.003141849],"category_scores_gemma":[0.009231656,0.0008091566,0.02385561,0.002014085,0.0003988194,0.0009249213,0.0009432124,0.002359701,0.0002444704],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001126238,"about_ca_system_score_gemma":0.0007957807,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003382783,"about_ca_topic_score_gemma":0.006152062,"domain_scores_codex":[0.9965939,0.001826163,0.0005845019,0.0005445289,0.0003015238,0.0001493676],"domain_scores_gemma":[0.9939593,0.004638013,0.0007748484,0.000240196,0.0002635306,0.0001241486],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.03302317,0.00007925207,0.003777011,0.06299099,0.8753579,0.00008060728,0.00004412519,0.001101566,0.0004651697,0.0001312879,0.0006479828,0.02230091],"study_design_scores_gemma":[0.005551584,0.0008079186,0.006863485,0.002622474,0.9816152,0.00006604793,0.00003049387,0.0003643485,0.000141797,0.0003365077,0.00156805,0.00003210862],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02524208,0.9724473,0.0007907641,0.0001925271,0.0002554016,0.00008836264,0.0006363439,0.00003055829,0.0003166688],"genre_scores_gemma":[0.4652638,0.5283287,0.002435203,0.001016712,0.0004517764,0.0002709288,0.001455131,0.00005796265,0.0007198687],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01125466,"threshold_uncertainty_score":0.03072631,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2985425094853917,"score_gpt":0.4549858454893279,"score_spread":0.1564433360039362,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}